PRONAL C1/4 CAPSULES 15 MG
CODEINE PHOSPHATE : 15 MG ACETYLSALICYLIC ACID : 330 MG CAFFEINE : 40 MG BUTALBITAL : 50 MG · DIN 02229735 · PRO DOC LIMITEE
Health Canada status: CANCELLED POST MARKET
What is PRONAL C1/4 CAPSULES?
PRONAL C1/4 CAPSULES 15 MG contains CODEINE PHOSPHATE : 15 MG ACETYLSALICYLIC ACID : 330 MG CAFFEINE : 40 MG BUTALBITAL : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02229735, held by PRO DOC LIMITEE, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 18-Jan-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02229735 |
|---|---|
| Brand name | PRONAL C1/4 CAPSULES |
| Generic / active ingredient | CODEINE PHOSPHATE : 15 MG ACETYLSALICYLIC ACID : 330 MG CAFFEINE : 40 MG BUTALBITAL : 50 MG |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 15 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA79 CODEIN, COMBINATIONS WITH PSYCHOLEPTICS |
| AHFS class | 28:08.08 ; 28:08.04.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 18-Jan-2013 |
| Original market date | 2009-06-25 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N02AA79 CODEIN, COMBINATIONS WITH PSYCHOLEPTICS. 6 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/2 | 50 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02554623 |
| APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/4 | 15 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02554615 |
| FIORINAL-C 1/2 | 330 MG | CAPSULE | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 00176206 |
| FIORINAL-C 1/4 | 40 MG | CAPSULE | ARALEZ PHARMACEUTICALS CANADA INC | MARKETED | DIN 00176192 |
| TEVA-TECNAL C 1/2 | 40 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00608181 |
| TEVA-TECNAL C 1/4 | 40 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00608203 |
| PHENAPHEN NO 2 CAP | 16.2 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909290 |
| PHENAPHEN NO 3 CAP | 16.2 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909312 |
| PHENAPHEN NO 4 CAP | 64.8 MG | CAPSULE | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 01909304 |
| PHENAPHEN NO.2 CAP | 16.2 MG | CAPSULE | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | DIN 02042851 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.